Pharmaceuticals, Biotechnology and Life Sciences
Baxter International, the company focused on nutrition therapy, has expand its nutrition care portfolio to include the new enteral ENFit syringe and accessory line for patients requiring tube feeding.
A newly formed biopharmaceutical company based in San Francisco, USA, has ensured funds for unlocking research of the therapeutic potential of Wnt signaling, a key for stem-cell maintenance and tissue regeneration.
U.S. President Donald Trump’s vow to roll back government regulations at least 75 percent is causing anxiety for some pharmaceutical executives that a less robust Food and Drug Administration would make it harder to secure insurance coverage for pricey new medicines.
Adocia plans to license its diabetes treatment products, especially its most advanced program BioChaperone Lispro. The company’s boss said that cash position of €58 million will enable the company to push BioChaperone Lispro into phase 3 clinical trial.
Gilead Sciences has announced data from two Phase 3 studies evaluating the safety and efficacy of Genvoya for the treatment of HIV-1 infection in treatment-naïve adults.
Moberg Pharma has posted net profit after tax of SEK 32.7 million (€3.45 million) which is up from SEK 25.5 million last year.
The global biosimilars market is expected to witness a steep growth owing to the patent expiry of blockbuster biologic drugs. The ability of biosimilars to reduce healthcare costs is another driving factor for this industry.
Eli Lilly and Incyte Corporation have won European Commission’s marketing authorisation for Olumiant (baricitinib) 4 mg and 2 mg film-coated tablets in Europe for the treatment of moderate-to-severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to, one or more disease-modifying antirheumatic drugs (DMARDs).
Gilead Sciences will present findings from a preclinical study evaluating HIV capsid inhibitors (CAIs) for potential use as a long-acting antiretroviral (ARV) treatment, at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.
Allergan has made another acquisition deal in expanding its medical aesthetics portfolio by buying Zeltiq Aesthetics for $2.475 billion.